AURIMOD GmbH

What AURIMOD GmbH does

AURIMOD GmbH is an Austrian privately-held medical device company headquartered in Vienna that develops VIVO, a Class IIa medical device delivering auricular vagus nerve stimulation (aVNS) for chronic pain management, with particular emphasis on back pain. Founded in 2015, the company operates with a lean organization of approximately 10–12 personnel spanning executive leadership (CEO Stefan Kampusch, COO Bernhard Fabian, CCO/Managing Director Manuel Leal-Garcia), R&D engineering, quality and supply chain, medical affairs, and customer success. The core technology consists of a minimal-invasive ear-worn wearable that electrically stimulates the auricular branch of the vagus nerve to trigger endogenous, sustainable pain relief, with therapy intensity adapted per patient using physiological feedback signals such as heart rate.

The product ecosystem pairs the VIVO hardware device with the VIVO Pal mobile application (available on iOS and Android), which functions as a digital pain diary for patients and a therapy-monitoring tool for physicians. Distribution is prescription-based through healthcare professionals (HCPs), supported by an exclusive HCP portal and conference presence at events such as the German Pain Congress, NYC Neuromodulation Conference, and Austrian medical meetings. The VIVO device carries CE 0483 marking under EU medical device regulations, and the company is an EU Horizon 2020 grant recipient funding clinical validation of aVNS in chronic back pain patients, with peer-reviewed publications on aVNS efficacy hosted on its website.

Revenue mechanics combine hardware sales of the prescription VIVO device with a potential recurring component via the digital VIVO Pal app, distributed primarily through HCP channels across the DACH region (Austria, Germany) with emerging presence in the United States and Thailand via conferences. No parent company, external investors, or disclosed funding amounts appear in the available data; non-dilutive EU Horizon 2020 funding is the primary publicly identified financial backing. Pricing is not disclosed publicly.

Name

AURIMOD GmbH

Legal name

AURIMOD GmbH

Website

https://aurimod.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

AURIMOD GmbH is a Vienna-based medical device company developing VIVO, a CE-marked auricular vagus nerve stimulation wearable for chronic pain management, distributed via healthcare professional prescription alongside a companion digital pain diary app.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)

akta.pro secondary industries

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG), Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices) (CRACAQAK)

Keywords

• Neuromodulation devices
• Pain management therapy
• Vagus nerve stimulation
• Wearable medical devices
• Chronic pain treatment

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales (VIVO): Sale of the VIVO aVNS device for chronic pain treatment. The device is a CE-marked medical device requiring healthcare professional prescription.
2. Digital Pain Diary App (VIVO Pal): Digital pain diary app available on iOS and Android for tracking pain progression and well-being, supporting both patients and physicians.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

AURIMOD GmbH develops and markets VIVO, a Class IIa CE-marked wearable medical device that delivers personalized auricular vagus nerve stimulation (aVNS) to trigger the body's own pain relief mechanisms for chronic pain patients. The device uses physiological feedback such as heart rate to individually adapt therapy. The offering is complemented by VIVO Pal, a companion iOS/Android digital pain diary app for documenting and tracking therapy progress for both patients and their attending physicians.

Product overview

AURIMOD GmbH offers VIVO, a unified medical device ecosystem consisting of two integrated products: VIVO (the core Class IIa medical device for personalized auricular vagus nerve stimulation therapy) and VIVO Pal (the companion digital pain diary mobile app). Both products are designed to work together as part of a patient-centered, medication-free pain management system developed under an EU Horizon 2020 project. The development pipeline also includes future work on an integrated pain management system for objective and personalized treatment of chronic pain.

Differentiator

Problem solved

Functional benefit

Brands

• VIVO: Auricular vagus nerve stimulation (aVNS) device for pain treatment
• VIVO Pal App

Products and services

• VIVO Class IIa CE-marked minimal-invasive wearable medical device for personalized auricular vagus nerve stimulation (aVNS) that triggers the body's own sustainable pain relief. The device uses physiological feedback such as heart rate to individually adapt therapy for each patient, targeting healthcare professionals who prescribe it for chronic pain patients.
• VIVO Pal App Digital pain diary mobile application available on iOS and Android for documenting and tracking pain progression and well-being, supporting both patients and their attending physicians in monitoring therapy outcomes.

Quantifiable outcome

• More than 30% of chronic pain patients suffer from severe limitations despite treatment

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Partner OrganizationsminorOthersAcknowledged support from partners on the team page with a partner logo wall displayed, but specific partner organizations are not named in the source material.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aurimod-gmbh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AURIMOD GmbH